Innate Pharma Adopts New Governance Structure Following AGM

Innate Pharma SA ( (FR:IPH) ) has provided an announcement.

Innate Pharma S.A. announced the results of its Annual General Meeting held on May 22, 2025, where it transitioned from an Executive Board and Supervisory Board governance structure to a Board of Directors model with a Chief Executive Officer. This change, which includes the appointment of Mrs. Irina Staatz-Granzer as Chairman of the Board and Mr. Jonathan Dickinson as CEO, aligns with international standards and aims to enhance value creation for stakeholders.

The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.

More about Innate Pharma SA

Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches to harness the innate immune system, including multi-specific NK Cell Engagers via its ANKET® platform, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs). Innate Pharma collaborates with biopharmaceutical companies like Sanofi and AstraZeneca to advance research and development.

Average Trading Volume: 128,955

Technical Sentiment Signal: Sell

Current Market Cap: €181.4M

For detailed information about IPH stock, go to TipRanks’ Stock Analysis page.